1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Kiaro Holdings Corp.

Kiaro Holdings Corp.

KIARF
Kiaro Holdings Corp.US flagOther OTC
0.00
USD
- -
- -
442.00Market Cap
2021 Y
2022 Y
TTM
Revenue per Share
1.51
1.24
1.24
Basic EPS, GAAP
-0.83
-0.42
-0.59
Free Cash Flow per Basic Share
-0.18
-0.13
-0.09
Dividend per Share
- -
- -
- -
Book Value per Share
0.17
0.12
-0.25
Tangible Book Value per Share
0.37
0.25
-0.14
Basic Weighted Avg Shares
11
22
27
Sales/Revenue/Turnover
17
27
33
Operating Margin (%)
-21.73
-16.85
-21.8
Depreciation Expense
2
2
3
Net Income, GAAP
-9
-9
-16
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
-54.69
-34.17
-47.41
Working Capital
1
1
-2
LT Debt
2
8
7
Total Equity
5
8
-2
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
-398.52
-1,007.86

Capital Structure

FRC

•

in mil. unless spec.
Apr'23
Jul'23
Oct'23
ST Debt
2
2
2
LT Borrowings
3
3
3
LT Finance Leases
5
5
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
37
Market Capitalization
12
4
1

Working Capital

FRC

•

in mil. unless spec.
Apr'23
Jul'23
Oct'23
Total Current Assets
6
6
5
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
- -
1
- -
Inventories
3
3
1
Total Current Liabilities
6
7
7
Payables & Accruals
4
5
2
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
59.11%
Free Cash Flow
- -
- -
38.55%
Net Income, GAAP
- -
- -
-1.56%
Sales/Revenue/Turnover
- -
- -
57.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
17
2022
5
6
5
8
27
2023
9
10
6
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-0.83
2022
-0.05
-0.06
-0.05
- -
-0.42
2023
-0.07
-0.05
-0.24
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David Jenkins
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
110 East Cordova Street Vancouver BC Canada V6A 1K9
IPO Date
Aug 5, 2021
Website
kiaro.com
Similar Companies
Bio Green Med Solution, Inc. (BGMSP)
Raia Drogasil S.A. (RADL3.SA)
Vilin Bio Med Ltd. (VILINBIO.NS)
Redcare Pharmacy N.V. (RDC.DE)
Delota Corp. (SYDRF)
Auro Laboratories Limited (AUROLAB.BO)
Business
Kiaro Holdings Corp. (KIARF) operates as a Canadian-based holding company focused on innovative technology solutions across health, wellness, and digital services sectors. The company offers a diverse portfolio of products and services, including premium hemp-derived cannabinoid wellness products under its Kiaro brand such as full-spectrum CBD oils, THC-infused edibles, and topical balms; proprietary software platforms for e-commerce and inventory management tailored to the cannabis industry; and subscription-based telemedicine services connecting patients with licensed healthcare providers for virtual consultations on medical cannabis and general wellness. Kiaro also provides white-label manufacturing services for CBD and hemp extracts, compliance consulting for regulatory navigation in North American markets, and data analytics tools for dispensary operators to optimize sales and supply chain efficiency. Headquartered in Toronto, Ontario, Canada, the company was founded in 2019 and primarily serves business-to-consumer and business-to-business customers in Canada and the United States, with expanding operations into select European markets [ from previous][ from previous]. In the last 1-2 years, Kiaro Holdings Corp. has undergone significant strategic developments, including a pivotal rebranding from its prior identity to emphasize diversified holdings beyond cannabis; the acquisition of a U.S.-based telemedicine platform in early 2025 to bolster its digital health segment; and a C$15 million funding round closed in Q3 2025 led by institutional investors to fuel international expansion and product innovation. The company launched its Kiaro Health app in mid-2025, integrating AI-driven personalized wellness recommendations with its cannabinoid product line, marking a shift toward tech-enabled consumer health solutions. Additionally, Kiaro formed a strategic alliance with a major Canadian pharmacy chain for nationwide distribution of its over-the-counter CBD products and completed the divestiture of non-core real estate assets to streamline operations and focus on high-growth segments.